- Advanced search
- Immuno Portal
- Malaria Portal
Ligand id: 6891
View more information in the IUPHAR Pharmacology Education Project: abatacept
|No information available.|
|Summary of Clinical Use|
|Used to treat moderate to severe rheumatoid arthritis and juvenile rheumatoid arthritis. In July 2017, FDA approval was extended to include treatment of active psoriatic arthritis.
A Phase II clinical trial (NCT00505375) has been completed, evaluating the ability of abatacept to stop autoimmune destruction of any remaining active β cells in patients recently diagnosed with type 1 diabetes mellitus- see  for an explanation of the rationale behind this therapeutic approach, and  which points to some of its drawbacks.
|Mechanism Of Action and Pharmacodynamic Effects|
|Binding of abatacept to CD80/86 (B7 proteins on antigen presenting cells) provides a negative feedback mechanism which results in T-cell deactivation. This action reduces active inflammation.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)